FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to methods for improving pharmacokinetics, increasing plasma concentration of methyl-3-((methylsulphonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or its salt and increasing wakefulness or reducing excessive sleepiness in the subject. Methods include orally administering to a subject (a) methyl-3-((methylsulphonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof; and (b) a CYP3A4 inhibitor.
EFFECT: use of a CYP3A4 inhibitor leads to an increase in the concentration of CYP3A4 leads to an increase in the concentration of methyl-3-((methylsulphonyl)amino)-2-(((4- phenylcyclohexyl)oxy)methyl)piperidine-1- carboxylate in blood plasma.
17 cl, 3 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF FLECAINIDE AS ANTICONNEXIN AGENT AND METHOD OF POTENTIATION OF EFFECTS OF PSYCHOTROPIC MEDICINES | 2014 |
|
RU2661026C2 |
| (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE FORMULAS | 2017 |
|
RU2764576C2 |
| NEW COMBINATIONS OF H3 RECEPTOR ANTAGONISTS AND NOREPINEPHRINE REUPTAKE INHIBITORS AND THEIR THERAPEUTIC USE | 2019 |
|
RU2809163C2 |
| CATAPLEXIS TREATMENT | 2014 |
|
RU2689984C2 |
| TREATMENT OF CIRCADIAN RHYTHM DISORDERS | 2013 |
|
RU2748386C2 |
| METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS (VERSIONS) | 2006 |
|
RU2417077C2 |
| COMPOSITIONS AND METHODS FOR TREATING INSOMNIA | 2015 |
|
RU2703297C2 |
| METHODS FOR TREATMENT OF GAUCHER DISEASE | 2018 |
|
RU2781242C2 |
| PHARMACEUTICAL COMPOSITION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME | 2018 |
|
RU2779262C2 |
| SUBSTITUTED DERIVATIVES OF 1, 2, 3, 4-TETRAHYDROISOQUINOLINE | 2005 |
|
RU2378257C2 |
